4//SEC Filing
Litton Mark James 4
Accession 0001415889-24-024680
CIK 0001620463other
Filed
Oct 2, 8:00 PM ET
Accepted
Oct 3, 7:07 PM ET
Size
8.2 KB
Accession
0001415889-24-024680
Insider Transaction Report
Form 4
Litton Mark James
DirectorPresident and CEO
Transactions
- Award
Stock Option (Right to Buy)
2024-10-03+325,000→ 325,000 totalExercise: $0.45Exp: 2034-10-02→ Common Stock (325,000 underlying) - Award
Restricted Stock Units
2024-10-03+325,000→ 325,000 total→ Common Stock (325,000 underlying)
Footnotes (3)
- [F1]Each restricted stock unit ("RSU") represents a contingent right to receive one (1) share of Issuer's common stock.
- [F2]One-third (1/3rd) of the RSUs shall vest on each of December 31, 2024, June 30, 2025 and December 31, 2025, subject to the Reporting Person continuing to be a Service Provider (as defined in the Issuer's 2020 Equity Incentive Plan (the "Plan")) through the applicable vesting dates.
- [F3]One-third (1/3rd) of the shares subject to the option shall vest on each of December 31, 2024, June 30, 2025 and December 31, 2025, subject to the Reporting Person continuing to be a Service Provider through the applicable vesting dates.
Documents
Issuer
Athira Pharma, Inc.
CIK 0001620463
Entity typeother
Related Parties
1- filerCIK 0001604834
Filing Metadata
- Form type
- 4
- Filed
- Oct 2, 8:00 PM ET
- Accepted
- Oct 3, 7:07 PM ET
- Size
- 8.2 KB